Key Points
- Insider purchase: Convatec Group insider Jens Viebke bought 24,400 shares at GBX 230 each, for a total investment of £56,120.
- Analyst sentiment remains positive: Eight analysts rate the stock Buy and one rates it Hold, producing a “Moderate Buy” consensus and an average price target of GBX 305.44.
- Stock and business profile: Shares opened at GBX 234.60, within a 52-week range of GBX 193 to GBX 259.30. Convatec develops medical products focused on wound care, skin care, and ostomy solutions.
Convatec Group PLC (LON:CTEC - Get Free Report) insider Jens Viebke purchased 24,400 shares of Convatec Group stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average price of GBX 230 per share, for a total transaction of £56,120.
Convatec Group Price Performance
Shares of CTEC stock opened at GBX 234.60 on Thursday. Convatec Group PLC has a 52-week low of GBX 193 and a 52-week high of GBX 259.30. The company has a debt-to-equity ratio of 121.83, a quick ratio of 0.96 and a current ratio of 1.93. The firm has a market capitalization of £4.50 billion, a P/E ratio of 37.84, a P/E/G ratio of 0.93 and a beta of 0.77. The stock has a 50 day moving average price of GBX 223.38 and a 200 day moving average price of GBX 217.63.
Analyst Upgrades and Downgrades
Several brokerages have commented on CTEC. Berenberg Bank cut their price objective on Convatec Group from GBX 340 to GBX 335 and set a "buy" rating on the stock in a research report on Friday, September 11th. Peel Hunt reiterated an "add" rating and set a GBX 270 target price on shares of Convatec Group in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a GBX 315 target price on shares of Convatec Group in a research report on Wednesday, August 5th. Jefferies Financial Group reissued a "buy" rating and set a GBX 300 target price on shares of Convatec Group in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada restated an "outperform" rating and issued a GBX 315 price target on shares of Convatec Group in a report on Monday, August 3rd. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of GBX 305.44.
Check Out Our Latest Stock Analysis on Convatec Group
Convatec Group Company Profile
(
Get Free Report)
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
